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1. Introduction 
 
The guidelines presented here have been developed through consultation with PATHWAY-27 
project partners to provide practical guidance for designing, implementing and reporting pilot 
intervention studies using bioactive enriched foods (BEF). These guidelines update and 
complement previously published guidance documents, but are unique in providing practical 
information and troubleshooting based on the PATHWAY-27 pilot studies. 
 
The aim of PATHWAY-27 is to evaluate the effectiveness of BEF containing docosahexaenoic 
acid (DHA), anthocyanins (AC) and beta-glucan (BG) alone or in combination, on improving 
risk factors of the metabolic syndrome (MetS). These compounds were chosen for their known 
effects as single compounds, and considered as ingredients of BEF in three different widely 
consumed food matrices (dairy, bakery and egg products). This approach of using BEF, 
compared to single pure compounds, will allow a better understanding of possible bioactive 
synergisms and bioactive-matrix interactions. This knowledge will increase the potential for 
exploitation of bioactive and BEF commercialization by the food industry. 
 
Previous guidelines by Welch et al., 2011 (1) that describe the designing, conducting and 
reporting of human intervention studies to evaluate the health benefits of food provide a good 
introduction to the subject for anyone considering undertaking such a research study. 
Additionally, there are useful publications describing some of the challenges faced when 
implementing a human dietary intervention trial. These include articles by Crichton et al., 2012 
(2) and Yao et al., 2013 (3) which discuss the difficulties of participant compliance and blinding. 
 
More recently, guidance from the EU-funded project BACCHUS for the design and 
implementation of human dietary intervention studies testing effects of dietary bioactive 
peptides and polyphenols on cardiovascular health in humans (4), has provided a useful toolkit 
to assist substantiation of health claims related to cardiovascular health. Furthermore, the 
PATHWAY-27 project is developing two guidance papers, for the scientific community and for 
the food industry, relating to the substantiation of health claims on BEF. These guidance 
papers, which will be published at the end of the project (deliverables D7.4 and D7.5) after 
consultation in two stakeholder workshops, will complement earlier guidelines and be 
particularly useful for small and medium sized enterprises (SMEs) looking for a competitive 
advantage in the EU market. For a health claim to receive a positive evaluation from the 
European Food Safety Authority (EFSA) ƚŚĞƌĞŵƵƐƚďĞ ?ŐĞŶĞƌĂůůǇĂĐĐĞƉƚĞĚƐĐŝĞŶƚŝĨŝĐĞǀŝĚĞŶĐĞ ?
to substantiate the claim. EU legislation, Regulation (EC) No. 1924/2006, dictates that the food 
or nutrient in question must be well characterised and shown to have a beneficial 
physiological effect (5). The cost of conducting robust scientific research coupled with often 
limited research and development (R&D) budgets is a barrier for successful applications by 
SMEs (6). 
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A pilot trial is a small-scale study that is used to test the physiological effects and participant 
acceptance of prototype formulations in order to select food products to be tested in a larger 
scale trial. The pilot is also a great opportunity to test the data collection methods, procedures 
and logistics that can provide early identification of problems in order to find suitable solutions 
that can be implemented to improve the quality and efficiency of the main trial. 
 
With examples gathered from the PATHWAY-27 project, this guidance document describes 
the requirements for the formulation and production of BEF, the design and conductance of 
a pilot trial, and how the data and information gathered can be used to inform further larger 
trials and the best practice for public reporting.  
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2. Designing a pilot study 
 
2.1. Production of bioactives 
 
To produce BEF it is important to provide ingredients with a high enough concentration of the 
bioactive compound(s) as well as ensuring the safety of the ingredients.  
 
The ingredients containing the bioactive components of interest must be well characterized. 
The production process should be described along with the chemical composition and 
concentration of bioactives. The concentration of bioactives in the ingredients should be 
consistent; large fluctuations will affect the quantity of the ingredient required to produce 
BEF. Alteration of one key ingredient may necessitate a reformulation of other ingredients, 
such as water. Consequently, this may alter the stability, quality and shelf-life of the BEF. 
 
The microbiological criteria and their limits of acceptability for the bioactive ingredients must 
be established considering microbiological risk assessments associated with the type of 
product.  
 
The concentration of the bioactive to be administered to volunteers must be set before 
starting the trial, based on data in the literature on the effectiveness of the bioactive itself on 
the specific endpoint(s) to be measured. The selection of this concentration drives the choice 
on the ingredient containing the bioactive. 
 
2.2. Formulation of bioactive-enriched food 
 
2.2.1. BEF formulation 
 
The formulation of foods enriched with bioactive ingredients represents a big challenge for 
food technologists. Characteristics related to composition, digestibility, bioactive accessibility, 
shelf-life, sensory properties and consumer acceptance must be optimized. Food formulation 
is initially conducted on a lab-scale and then increased for production in a manufacturing 
setting. 
 
As reported above, the concentration of the bioactive to be administered to volunteers is a 
crucial point. It is usually set based on results in the literature considering the same or similar 
endpoint(s). Once the concentration is set, the possibility to include it in one portion of the 
BEF must be checked. Since portion size is different for different food categories, the 
bioactives concentration per 100 g could be different in different foods. Notably, a high 
bioactives concentration in the BEF due to a small portion size could negatively affect its 
sensorial characteristics. 
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The PATHWAY-27 project represents a useful example on how to manage the formulation and 
choice of the right products to be used in pilot studies. The PATHWAY-27 pilot studies aimed 
to test 5 different bioactive enrichment types  W docosahexaenoic acid (DHA), beta-glucan (BG) 
and anthocyanins (AC), individually or in combination of DHA+BG and DHA+AC, within each of 
3 different food matrices  W bakery, dairy and egg. In the beginning of the project, within each 
food matrix at least three different foods were considered as possible vehicles to deliver the 
bioactive ingredients (Errore. L'origine riferimento non è stata trovata.). Formulation of the 
food products was decided using factorial design to simultaneously evaluate the effect of 
ingredients, stabilizers, salt concentration, pH, and processing parameters such as mixing 
time/speed, processing time/temperatures, on the production process. Particular attention 
was devoted to: 
 
- Optimizing the ratio of bioactives, proteins, fats and other ingredients, 
- Choosing appropriate ionic strength/pH parameters to control the aggregation of 
hydrophilic macromolecules to obtain discrete colloidal particles, 
- Selecting suitable excipients to direct self-assembly of components to obtain colloidal 
particles, 
- ^ĞůĞĐƚŝŶŐ ƐƵŝƚĂďůĞ ƐƚĂďŝůŝǌĞƌƐ ƚŽ ĐŽŶƚƌŽů  ?ŚŽƐƚ-ŐƵĞƐƚ ? ŝŶƚĞƌĂĐƚŝŽŶ ďĞƚǁĞĞŶ
polysaccharides and AC. Emphasis was placed on studying the dissociation of colloidal 
structures at varying pH, ionic strength and enzymatic attack to modulate the release 
of the bioactive in chemically unaltered forms. 
 
Table 1 Food products considered for each matrix in the PATHWAY-27 project 
Bakery Dairy Egg 
Buns Pudding Pancake 
Bread sticks Combined dessert Omelette 
Biscuits Milkshake Beverage 
 UHT milk Custard 
 Melted cheese  
 
During the design and development of PATHWAY-27 BEF problems occurred. Some were 
general across all BEF, for example using AC imparted a distinctive purple, sometimes green 
colour, and some were specific to the food type, for example high viscosity of batter for 
pancakes containing BG. The challenges and solutions are summarized in Errore. L'origine 
riferimento non è stata trovata.. 
 
Table 2 Problems faced during the design and development of PATHWAY-27 BEF 
Goal Problem Potential solutions 
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All products should be 
stable at room temperature 
for at least 3 weeks. 
- Dairy and egg based 
foods are typically 
stored at 4°C to maintain 
adequate 
microbiological safety. 
- The addition of 
preservatives and 
vacuum/modified 
atmosphere packaging. 
- Proposal for multiple 
deliveries from the 
manufacturer to the 
recruitment centres 
(RCs) and from the RCs 
to participants. 
Enrich products with 3 g BG 
per portion 
- BG produced highly 
viscous solutions when 
mixed with liquid egg 
that are difficult to 
handle in the machines 
used to produce egg 
products. 
- Some products 
developed unacceptable 
organoleptic properties. 
- Less crisp texture of 
bakery biscuit BEF 
compared with control 
due to requirement for 
extra water. 
- Inclusion of more water 
in the formulation to 
reduce viscosity. 
- Use of flavour additives 
to mask unpleasant 
flavours. 
- Longer baking time to 
produce a drier biscuit. 
Enrich products with 320 mg 
AC per portion. 
- AC produced a strong 
violet colour in all BEF. 
- Loss of textural quality 
during storage of bakery 
buns. 
- Low density and high 
staling rate of bakery 
buns. 
- Unacceptable taste of 
bakery buns due to 
preservatives. 
- Microencapsulation of 
the AC. 
- Use of coloured 
ingredients containing 
no polyphenols to mask 
the colour. 
- Recipe modification to 
change the type of 
bakery bun. 
- Reduction of 
preservatives.  
Enrich products with 250 mg 
DHA per portion. 
- DHA imparts a fish-like 
aroma and taste to the 
foods. 
- Use of flavours and 
aromas to mask the 
DHA. 
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- Use DHA as part of a 
phospholipid or enriched 
egg powder ingredient 
 
During the product development process, it became apparent that some BEF were not 
technically feasible. It was therefore decided that UHT milk, melted cheese and custard would 
not be further considered. 
 
 
2.2.2. BEF digestion and bioaccessibility of bioactive compounds 
 
Bioaccessibility of a compound or nutrient describes the fraction that is released from its food 
matrix and solubilized in the gastrointestinal tract so becoming potentially available for 
intestinal absorption. Bioactive bioaccessibility could be even more relevant than bioactive 
concentration in the BEF, and it could be dependent on the food matrix. It is therefore 
mandatory to understand the influence of the food matrix on BEF digestibility and bioactive 
accessibility. In addition, it could help to select the BEF with the best overall performance for 
the intervention trial. 
 
A model for static in vitro digestion was recently developed and reported by COST action 
FA1005, INFOGEST (7). This model comprises oral, gastric and intestinal phases and considers 
the presence of digestive enzymes, electrolyte composition, temperature, calcium and bile 
salts, pH and time. It can be applied to various endpoints and can be adapted to accommodate 
specific requirements. 
 
Based on PATHWAY-27 experience, bioaccessibility of bioactives is influenced by the food 
matrix and in some cases the simultaneous enrichment with two bioactives. Differences were 
also observed between two foods within the same matrix. In the PATHWAY-27 project results 
from digestion and bioaccessibility studies were used to assist the selection of BEF for use in 
the pilot intervention trial. 
 
2.2.3. Consumer acceptance and sensory analysis of BEF 
 
Understanding consumer acceptance and determining the sensory profile of BEF is an 
important part of developing BEF for an intervention trial. The use of not well-accepted foods, 
or foods with bad sensorial characteristics affects participant compliance during the 
intervention. Accordingly, in the PATHWAY-27 project, 45 BEF were formulated (3 foods per 
matrix, with 5 enrichment types per food). All BEF were pre-screened and one product from 
each matrix, with the worst sensory characteristics, was excluded to leave 30 BEF for further 
sensory and consumer acceptance profiling. 
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Consumer acceptance was measured using first an online survey followed by tasting sessions. 
The online survey consisted of four parts: a) to collect socio-demographic data, b) to explore 
behaviour and attitudes towards health and diet, c) to understand attitudes towards 
functional foods, and d) to evaluate acceptance of the PATHWAY-27 BEF using photos. 
 
Following on from the online survey, consumers were invited to tasting sessions where they 
were asked to rate the appearance, aroma, flavour and texture of the BEF using a 9-point 
hedonic scale. In addition to these main attributes an extended list including specific food 
colours, aromas, flavours, aftertaste and textures were scored using a 5-point JAR-scale. 
Consumers were also asked to indicate how much they liked the BEF overall and how likely 
they were to buy the products, taking into consideration the healthiness of the food. Following 
this exercise, one food from each matrix was excluded (breadsticks, egg desert and pudding). 
 
A sensory panel was trained in compliance with ISO standards to describe attributes of the 
foods and rate them on a 0-9 category scale. This is called sensory profiling and provides more 
specific information that can help technologists improve the products.  
 
The results of consumer acceptance testing and sensory profiling were used to support the 
selection of BEF for the pilot intervention trial. The selection of the right product is crucial for 
the intervention. If it is not well-accepted by participants the study compliance will be low. 
This can result in a high number of dropouts reducing the power of the study, or to a 
consumption of the food lower than declared by the volunteer. This can represent an 
important bias in the study outcome. 
 
2.3. Shelf-life evaluation of BEF 
 
The chemical, microbiological and sensorial quality of BEF should be established under the 
standard storage conditions of the food product. The results will help to characterize the BEF 
and ensure the provision of safe, stable and acceptable products for the duration of the trial. 
 
2.3.1. Chemical stability 
 
2.3.1.1. Bioactive compounds 
 
It is essential to ensure that participants of the study receive the effective dose of the bioactive 
compound(s) for the duration of the trial. It is to be expected that the storage conditions 
(temperature and time), along with the food matrix and bioactive type will affect chemical 
stability. The bioactive content of BEF should be measured immediately after production and 
then at set intervals during the storage period under the standard storage conditions. 
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During the design phase of the study, it is important to establish protocols for the chemical 
analysis of bioactive compounds in BEF. Different analytical methods are likely to yield varying 
results so the available methods should be evaluated, tested and selected in advance. It is 
important to consider that different food types may require different extraction methods, for 
example the extraction method for anthocyanins in PATHWAY-27 bakery products was 
different from the extraction method for dairy and egg products.  
 
Bioactive retention is an important parameter of BEF formulation. In PATHWAY-27 AC were 
found to degrade during food processing and storage of bakery products. To compensate for 
losses during processing, higher levels of AC were included in the starting formulation. In 
addition, it was found that bread buns lost more AC compared to biscuits. This factor 
influenced the choice of biscuits over bread buns in the final selection of BEF for pilot studies. 
During the PATHWAY-27 studies, bioactive levels were measured for each batch of food 
produced using standardized analysis protocols. The evaluation of bioactive retention can 
prevent bias in the intervention study due to administration of bioactive amounts lower than 
required. Pilot studies are usually quite short, so shelf life and bioactive retention do not 
represent a big problem, but they must be carefully considered in the light of the further 
intervention that is usually longer than the pilot. 
 
2.3.1.2. Food matrix 
 
While developing new functional food products containing bioactive compounds, it is current 
practice to assess the stability of the enrichment ingredients as it may be influenced by their 
interaction with the matrix, the latter exerting either a protecting or destabilizing action. The 
other perspective explored by the PATHWAY-27 project is about the effect of the enrichment 
ingredients on the stability of the matrix, as it is assumed that the bioaccessibility of the other 
nutrients in the food product remain unaltered. Nuclear Magnetic Resonance (NMR) 
spectroscopy is a state-of-the-art technique that can be utilized to characterize the food 
products and assess their molecular profiles. Since high-resolution NMR will only detect 
molecules that are soluble in the extraction medium it does not directly observe the solid food 
matrix. Thus, matrix stability is measured by analysing the soluble molecules that are released 
by the solid phase, that are disappearing by binding to the matrix or are consumed by 
degradative reactions, during storage. 
 
Firstly, different products for each food category must be comparatively analysed. In the case 
of PATHWAY-27, two products belonging to bakery, dairy and egg were analysed: buns and 
biscuits, milkshakes and combined desserts, and pancakes and omelettes. At the starting 
storage time, all food products with the same food matrix were compared to each other, 
independently of the enrichment type. To evaluate the contribution of the matrix-related 
substances on the complete molecular profile, only the spectral data points exerting an 
intensity change below a determined threshold of variation, among the 5 enrichments of the 
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same product are considered as descriptors of the matrix. In addition, the subset of selected 
points must constitute an important fraction of the whole spectral data set, to be a meaningful 
representative of the soluble fraction of the matrix. These data points are the spectral features 
that will be evaluated during the shelf-life, by measuring their variance within each product 
during three storage time-points (for example, T0, T15 and T30 days). 
 
In the PATHWAY-27 study, it was found that milkshakes were the products with highest 
stability within the dairy category, whilst pancakes were more stable than omelettes among 
egg products, and biscuits and buns had the same stability. 
 
Additionally, a comparative evaluation among the different enrichment types within the same 
food matrix should be addressed to avoid combinations of bioactive ingredients and food 
matrix which result in poorly stable food products. Of the PATHWAY-27 BEF selected for the 
pilot intervention trial, biscuits were shown to have a relatively stable matrix independent of 
the specific enrichment type; the most stable pancake enrichment was DHA+AC; and DHA+BG 
enriched milkshakes had the longest stable molecular profile. 
 
2.3.2. Microbiological stability 
 
The microbiological safety of BEF is one of the most important criteria for selection because it 
is essential not to cause ill health to participants during the trial. In the PATHWAY-27 project 
two factors were considered: 
 
1) The growth of intrinsic microorganisms during storage (shelf-life study), and 
2) The ability of inoculated risk microorganisms to grow in the stored products (challenge 
test). 
 
The microbiological criteria that are analysed along with limits of acceptability must consider 
risk assessments associated with the type of food product. This is based on regulations, 
standards, review of literature and the manufacturers own experience with similar types of 
products. A challenge test may not be considered necessary if the food product is unlikely to 
facilitate the growth of pathogens, for example foods that are frozen immediately at the site 
of production or provided as a dry powder. 
 
During production and microbiological testing of milkshake BEF for the PATHWAY-27 pilot 
study, Enterococcus spp. was detected in all samples. The levels were acceptable according to 
regulations in the country of manufacture, however at the time it was unknown whether the 
levels were acceptable in the country where the milkshake BEF would be trialled. Further 
microbiological testing was carried out to determine the source of the contamination and 
expert advice was obtained. Testing showed that the contamination came from the original 
non-enriched milkshake powder rather than from the bioactive enrichment. Advice from dairy 
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specialists confirmed that Enterococcus spp. is commonly reported in milk products and that 
it is difficult to find products with zero-levels. After many discussions, it was agreed that the 
RC testing the milkshake BEF would be able to use the products, however the start of the pilot 
trial at this RC was delayed by one month. 
 
2.3.3. Maintenance of sensory quality 
 
BEF must maintain the sensory quality during the shelf-life of the product to maintain a high 
compliance in participants. Having previously determined the sensory attributes of the BEF, a 
trained panel should assess the products at set intervals during the predetermined safe shelf-
life period. 
 
2.3.4. Nutritional evaluation 
 
BEF must be evaluated from the nutritional point of view, and they must comply with the 
indication of good nutrient profile provided by EFSA. In case the level of nutrient such as 
saturated fat or sodium is too high, the food must be reformulated or discarded. Using 
PATHWAY-27 as experience, we can cite that the original milkshake formulation needed 
modifications using skimmed milk instead of whole milk to reduce the high level of saturated 
fat. This reformulation allowed obtaining a good nutritional profile while retaining acceptable 
sensory properties. 
 
 
2.3.5. Consumer perception 
 
Independent from their nutritional value BEF must be perceived as healthy by consumers. In 
PATHWAY-27, BEF were nutritionally evaluated and their nutrient profile was acceptable, but 
consumer perception was not used to reformulate the study BEF. The selected products were 
perceived as energy-dense and increasing the possibility of weight gain and this reduced the 
number of volunteers willing to enter the study. Based on PATHWAY-27 experience the 
evaluation of consumer perception should be included in the list of determinants for the 
choice of the BEF to be used in the intervention. 
 
The integrated analysis of all the above-mentioned parameters allows the choice of the most 
suitable food to be used in the intervention. In PATHWAY-27, to select the three foods, one in 
each matrix, to be used in the pilot studies, the method of the "decision sieve" was used. 
Briefly, some parameters were set as mandatory (microbiological safety, chemical stability of 
bioactive compounds, and nutritional profile), and foods not complying were immediately 
discarded. Secondary parameters used for BEF selection were: bio-accessibility of bioactive 
compounds, Sensory characteristics, Ease of preparation, ease of storage, and food matrix 
stability). 
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2.4. Writing a research protocol 
 
The description that follows considers the experience built in PATHWAY-27, but it can be used 
for other matrices and bioactives than those used in the project. It can also be used when a 
single, specific bioactive should be used to enrich a specific food matrix, as often happens 
when the producer is a SME. In this case the procedure is easier, but it allows the optimization 
of the newly formulated food. 
 
A research study protocol is a document that provides detailed information about the 
background and rationale for the trial and the intervention and activities expected of the 
participants. It will demonstrate to a Research Ethics Committee (REC) that the study is 
scientifically valid and has been ethically designed to safeguard the health and wellbeing of 
the participants. REC members will use the protocol as a basis for providing approval/a 
favourable opinion for the trial. Researchers involved in the study will use the protocol as an 
operational handbook. 
 
When writing a research study protocol, it is essential to follow the relevant regulations and 
good practice guidelines for conducting a research study using human participants. There may 
be some variation between national guidelines, however, generally in the European Union 
(EU), these will be based on EU legislation and will adhere to the same governing principles.  
 
The World Health Organization (WHO) have produced a comprehensive Practical Guide for 
Health Researchers (8) that covers ethics; planning; implementation; analysing, interpreting 
and communicating results; and writing a scientific manuscript for publication. The document 
also includes an extensive list of resources to assist a literature search. Regulation (EU) No 
536/2014 for clinical trials on medicinal products for human use (9) and the ICH Guidelines for 
Good Clinical Practice E6(R1) (10) both provide information to ensure the rights, safety and 
well-being of study participants are maintained. The WHO also provide a simple, user-friendly 
overview of the recommended format for a research protocol (11). 
 
A research study protocol should follow a standard format. Each of the sections to be included 
are summarised in this document and, where relevant, links to more detailed resources are 
provided. 
 
2.4.1. Scientific background and rationale 
 
Performing a review of current literature in the subject area of interest is an essential first 
step to determine the need for, and feasibility of, the proposed research. Some questions that 
must be considered include: 
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- Has research using the pure bioactive been conducted before? 
- Has the effective dose of the bioactive been established already? 
- What is (are) the main endpoint(s)? 
- Who is the target population? 
- Have similar BEF been produced before? 
 Have they been studied in intervention trials? 
 Have they been studied in animal models? 
- Which food matrix should be selected? 
- Is outcome variable(s) direct measures of the claimed effect? 
- Are the assessment methods appropriate? 
 
Four main gaps in current knowledge about the health effects of bioactive compounds that 
were identified will be addressed by the following strategies of the PATHWAY-27 project: 
 
1) Considering bioactives administered as BEF within the everyday diet rather than as 
discrete compounds there is a need to evaluate: 
a. Possible interactions of bioactives and the food matrix. 
b. Possible effects of the food matrix on the outcome. 
2) Bioactive effectiveness will be evaluated against measureable, physiologically-relevant 
endpoints. 
3) In vitro and in vivo studies will be integrated to better understand the clinical effect of 
the bioactives and their underlying mechanism(s) of action. 
4) The high cost of intervention studies that is often a barrier to SMEs and reduces their 
ability to develop new products will be shared between SMEs to optimise their 
cooperation. 
 
The BACCHUS guidance for the design and implementation of human dietary intervention 
studies for health claim submissions provides detailed information of the approaches for 
conducting a literature search, with useful examples (4). They describe six steps to retrieve 
relevant literature and aspects to consider when evaluating human studies. The steps are 
summarised below: 
 
1) Define the problem and the study question. 
- Use a PICO (participants, intervention, comparison, outcome) search strategy  
2) Use online databases to search for papers related to the hypothesis. 
- For example: PubMed, EBSCO, Web of Science, MEDLINE, CAB Abstracts, Scopus, 
etc. 
3) Identify key terms associated with the study question and related terms. 
- For example: anthocyanins, metabolic syndrome. 
4) Create a search strategy using the search terms identified. 
5) Evaluate the search results. 
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6) Evaluate the scientific quality of each study. 
 
2.4.2. Study hypothesis/research question and objectives 
 
A research study is based on a clear research question or hypothesis that it is designed to 
answer. The objectives are statements of the research questions and should be simple, 
specific and stated in advance (11). There may be an overall research question/hypothesis 
that initially generates the research study, however a feasibility or pilot study that is 
conducted prior to a main randomised controlled trial (RCT) could have separate objectives. 
For example, a pilot study can be used to test procedures, estimate recruitment, compliance 
and retention, and determine sample size (12). The data collected from a pilot trial are not 
necessarily expected to provide statistically significant results. 
 
In PATHWAY-27, three pilot studies were used to select the most effective BEF for each food 
matrix to be tested in a larger intervention trial. This preliminary selection in pilot studies 
greatly reduced the cost of the larger intervention trial. In fact, each pilot allowed the selection 
of the most effective enrichment in a specific food matrix, so considering the food 
matrix/bioactive interaction. In total, 15 BEF were tested in the pilot studies and three of them 
were selected for the main RCT. To test all foods in a long term, multi-centre study would have 
been extremely costly. To perform a single pilot to verify the most effective enrichment, and 
then use it in all matrices would have not considered the food matrix interaction. The design 
of PATHWAY-27 pilots is therefore a good compromise to reduce cost avoiding the a priori 
assumption that one enrichment fits all matrices. A similar design can be useful when the 
same food company needs to test different possibilities or when different companies (mainly 
SMEs) producing different products wish to share the cost of the intervention. 
 
 
 
2.4.3. Trial design, randomisation and blinding 
 
2.4.3.1. Trial design 
 
The most rigorous research study is a RCT. A placebo group is typically used to demonstrate a 
cause and effect relationship between the treatment group and the outcome (13). Random 
allocation to the treatment prevents systematic differences occurring that can affect the 
outcomes. Since it is possible that the measured outcomes may be a result of simply 
consuming the study foods, rather than the bioactive enrichment, the control group acts to 
validate the results of the treatment group. However, it may not be necessary to use a control 
group for a pilot trial because the objective of the pilot trial may be to select the most 
promising formulation, rather than provide statistically conclusive evidence of an effect.     
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There are two types of design that can be used with a RCT, these are crossover or parallel-
arm. In a crossover study, each participant will receive both treatment and control, the order 
in which they receive this can be randomly assigned. This type of study can be more cost 
effective since fewer participants are required to achieve the statistical power (14). However, 
a crossover study has the disadvantage that the first intervention effect may carry over to the 
second intervention and confound the outcomes. Another disadvantage of the crossover is 
that participants will be required to take part in the study for twice as long which could lead 
to a higher rate of drop-outs or lower compliance. A crossover study may also affect blinding 
of the trial if the placebo and treatment foods are noticeably different. A parallel study will 
compensate for the disadvantages of the crossover design; however, it is likely to require a 
higher number of participants per treatment group. A parallel design was chosen for the pilot 
studies to enable a more rapid selection of BEF for the subsequent main RCT. 
 
2.4.3.2. Types of randomisation 
 
Several methods have been proposed for the random assignment of participants to the study 
groups in clinical trials. These include simple randomization, block randomization, and 
stratified randomization. Simple randomization is the equivalent of flipping a coin, and the 
random allocation of subjects into the groups will probably yield balanced group sizes in large 
trials, but not necessarily in smaller ones. The block randomization method will result in equal 
sample sizes among groups, as it uses small blocks with sizes that are multiple of the number 
of treatment groups. The stratified randomization method will also control for the influence 
of covariates such as gender or (predefined) age groups, etc. Thus, not only will it yield equal 
ŐƌŽƵƉƐŝǌĞƐ ?ďƵƚĂůƐŽƐƵďũĞĐƚƐ ?ďĂƐĞůŝŶĞĐŚĂƌĂĐƚĞƌŝƐƚŝĐƐǁŝůůďĞƐŝŵŝůĂƌďĞƚǁĞĞŶŐƌŽƵƉƐ ?WƌĂĐƚŝĐĂů
implementation of this method is very difficult; hence this technique is rarely used in RCTs.  
To achieve equal group sizes among the five PATHWAY-27 treatment groups the block 
randomization method was used for each of the three study centres. The allocation of 
participants to the different groups was carried out based on predefined randomisation lists 
created separately for each recruiting centre. All three randomisation lists were prepared with 
a block size of 5 and with an allocation ratio of 1:1:1:1:1.  
 
2.4.3.3. Blinding 
 
Blinding is the procedure used in a trial to avoid bias by preventing participants and/or 
researchers being aware of the treatment allocation. There are four categories of blinding 
[adapted from (15)]: 
 
1) Unblinded: all parties are aware of the treatment allocation. 
2) Single-blind: Only the participants are unaware of the treatment allocation. 
3) Double-blind: The participants and researchers are unaware of the allocation. 
4) Triple-blind: Participant, researchers and data analysts are unaware of the allocation. 
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When using a food product, it is not always easy to formulate an exact matching placebo, 
although matching macronutrients and other key nutrients, such as salt, is essential. BEF and 
placebo that differ in characteristics other than the food or constituent may affect the claimed 
health effect. Consequently, the study design would be considered not appropriate for the 
claim and that the study is at high risk of bias so no conclusions can be drawn (16). 
 
The bioactive ingredient used may have a characteristic that is difficult to disguise or provide 
a non-bioactive corresponding ingredient. For example, the PATHWAY-27 bioactive 
ingredients of docosahexaenoic acid (DHA) and anthocyanins (AC) give the foods distinctive 
characteristics. DHA tends to impart a fish-like odour to the foods and AC turns the foods 
purple (Figure 1). While the participants receiving the treatment, in a parallel-arm trial, are 
unable to compare their food with the placebo, it is possible for them to speculate about the 
group they have been assigned. It is important to ensure blinding to the research team 
allocating the foods to avoid influencing participants. For this reason, in PATHWAY-27 all BEF 
portions given to participants were individually wrapped in opaque packaging that was 
identical amongst treatment groups (Figure 2). 
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Figure 1 BEF and corresponding placebo products used in the PATHWAY-27 pilot studies. 1a = Biscuit BEF, 1b = Biscuit placebo; 
2a = Milkshake BEF, 2b = Milkshake placebo; 3a = Pancake BEF, 3b = Pancake placebo. 
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Figure 2 Packaging used in the PATHWAY-27 project. Clockwise from top left: biscuits, milkshake powder, pancakes 
 
2.4.4. Study population (participants) 
 
This section should describe the eligibility criteria to participation in the trial and depends 
whether a generally healthy population is required or if a specific health issue is being 
addressed.  
 
The criteria used for determining eligibility for the PATHWAY-27 pilot trial is listed in the 
following sections. It was intended that there would be a 1:1 ratio of male and female 
participants, however this was difficult to achieve in each RC and therefore this criterion was 
not adopted for the larger trial. 
 
2.4.4.1. Inclusion criteria 
 
MetS is the name given to a cluster of conditions that occur together more often than can be 
explained by chance. In 2009 a joint statement was published by world-leading authorities on 
cardiovascular disease and diabetes that harmonised the criteria by which MetS is diagnosed 
(17). The cut-off points for each condition associated with MetS is shown below, a diagnosis 
is made when 3 out of the 5 criteria are present. 
 
 
 
PATHWAY-27 - http://www.pathway27.eu/  
- Project funded under the Food, Agriculture and 
Fisheries, and Biotechnology theme (KBBE)   
 
 
21 
- EůĞǀĂƚĞĚǁĂŝƐƚĐŝƌĐƵŵĨĞƌĞŶĐĞ ?ŵĞŶA? ? ? ?Đŵ ?ǁŽŵĞŶA? ? ?Đŵ ?
- EůĞǀĂƚĞĚĨĂƐƚŝŶŐƚƌŝŐůǇĐĞƌŝĚĞƐ ?A? ? ? ?ŵŐ ?Ě> ?
- Reduced fasting HDL-ĐŚŽůĞƐƚĞƌŽů ?ŵĞŶA? ? ?ŵŐ ?Ě> ?ǁŽŵĞŶA? ? ?ŵŐ ?Ě> ? 
- Elevated blood ƉƌĞƐƐƵƌĞ  ?ƐǇƐƚŽůŝĐ A?  ? ? ? ŵŵ,Ő ĂŶĚ ?Žƌ ĚŝĂƐƚŽůŝĐ A?  ? ? ŵŵ,Ő ? Žƌ
hypotensive treatment 
- EůĞǀĂƚĞĚĨĂƐƚŝŶŐŐůƵĐŽƐĞ ?A? ? ? ?ŵŐ ?Ě> ?
 
In the PATHWAY-27 pilot trial, volunteers, male or female, age 18 to 80 years, were eligible if 
they presented with two of the criteria for MetS, with at least one of them being elevated 
fasting triglycerides or low HDL cholesterol. 
 
After the start of recruitment, the eligibility criteria were amended to include participants with 
2, 3 or 4 of the conditions associated with MetS, providing that one of them was elevated 
fasting triglycerides or low HDL cholesterol. This change was implemented due to many of the 
volunteers who were screened that typically had altered triglycerides and/or HDL cholesterol 
plus increased waist circumference and raised blood pressure. 
 
2.4.4.2. Exclusion criteria 
 
Originally participants were excluded if three or more clinical criteria for MetS were met. This 
was later changed to reflect the amended inclusion criteria so that only volunteers meeting 
all 5 of the criteria for MetS were excluded. Additionally, major exclusion criteria were:  
 
- Regular drug therapy with impact on serum lipids;  
- Diabetes (fasting glucose > 1.26 g/L, or anti-diabetic treatment);  
- Recent history of cancer or cancer treatment (less than 2 years);  
- Active or recently diagnosed intestinal malabsorption or disorders associated with 
ŵĂůĂďƐŽƌƉƚŝŽŶ PƌŽŚŶ ?ƐĚŝƐĞĂƐĞ ?ƐŚŽƌƚďŽǁĞůƐǇŶĚƌŽŵĞ ?WĂŶĐƌĞĂƚŝĐinsufficiency, cystic 
fibrosis, Tropical Sprue, WŚŝƉƉůĞ ?Ɛ ĚŝƐĞĂƐĞ ? ĐŚƌŽŶŝĐ ƉĂŶĐƌĞĂƚŝƚŝƐ ? ŐĂƐƚƌŽũĞũƵŶŽƐƚŽŵy, 
surgical treatments for obesity, cholestasis, biliary atresia, parasite infections, 
HIV/AIDS  
- Familial dyslipidaemia;  
- Use of medication known to cause malabsorption: tetracycline, cholestyramine, 
thiazide diuretics, aluminium/magnesium hydroxide, colchicine, neomycin, 
methotrexate, methyldopa, and allopurinol, and laxatives  
- Illegal drug use, chronic alcoholism or active smoking;  
- IŶƚĞŶƐŝǀĞƉŚǇƐŝĐĂůĞǆĞƌĐŝƐĞ ?A? ?ŚŽƵƌ ?ǁĞĞŬ ? ? 
- Consumption of nutritional supplements containing DHA, BG or AC;  
- History of allergy or intolerance to any components used in BEFs, celiac disease, lactose 
intolerance, allergy to milk or egg proteins;  
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- Institutionalised patients, those who lack autonomy to consent or are unable to meet 
all examinations;  
- Women who are pregnant, lactating or actively trying to conceive;  
- Participation in other clinical trials that may impact on outcome;  
- Subjects deprived of their liberty by judicial or administrative decision.  
 
2.4.5. Sample size 
 
This is the number of participants required to detect significant differences between primary 
outcomes in each group. Estimating an adequate sample size has ethical and financial 
implications. It should be a large enough sample to provide reliable results but not too large 
that more participants than necessary are included. 
 
To perform a proper sample size calculation, the first and most important step is to formulate 
the null and the alternative hypothesis. Then the significance level and the power with which 
the sample size would be calculated will be set, together with specifying the smallest effect 
size that will be of scientific interest. Finally, most of the time, for the calculation to be 
performed an estimate of the standard deviation is needed  W which can be obtained from 
historical data  W from similar studies conducted in the past, or from a pilot study. After having 
all the necessary data, the calculation of sample size will be straightforward. There is little 
published guidance concerning how large a pilot study should be. General guidelines suggest 
different methods, for example, for using 10% of the PATHWAY-27 sample required for the 
full study (18).  
 
In the PATHWAY-27 main RCT, initial sample size calculation was based on results provided by 
a reference article, where a difference in the decrease in triglyceride levels of 0.11 mmol/l 
with standard deviations in the placebo and control groups of 0.34 and 0.31, respectively was 
obtained. Consequently, for the PATHWAY-27 main RCT a difference in the decrease of 
triglyceride levels of 0.12 with a common standard deviation of 0.35 was hypothesised. Based 
on historical data and adjusted values for multiple group comparisons to obtain a power of 
80% a sample size of 200 volunteers per group was calculated. According to suggestion from 
general guidelines, a sample size of 20 volunteers in each treatment group was therefore 
considered acceptable. Since each pilot focused on five treatments, the total sample size in 
each pilot was set as 100 volunteers. The sample size was then reduced due to the need of 
shortening the pilot duration, and set to about 70 in each group to accomplish the  “ƌƵůĞŽĨ
 ? ? ? ?ŝ ?Ğ ?ĂƚůĞĂƐƚ ? ?ƉĂƌƚŝĐŝƉĂŶƚƐŝŶĞĂĐŚŐƌŽƵƉĨŽƌƉŝůŽƚƐƚƵĚŝĞƐǁŝƚŚƉƌŝŵĂƌǇĨŽĐƵƐŽĨĞƐƚŝŵĂƚŝŶŐ
average values and variability for planning larger subsequent studies (19). 
 
The sample size in pilots allowed the selection of the most effective BEF to be used in the main 
RCT. Significant results were not expected in pilot studies, they needed to be able to 
discriminate the effectiveness of the different treatments. To do it was quite difficult in the 
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pilot with the lower sample size. Based on the PATHWAY-27 experience, it is clear that 
evaluation of sample size is particularly critical for a pilot study. The statement  “EŽƐĂŵƉůĞ
size justification is needed because of the piůŽƚŶĂƚƵƌĞŽĨƚŚĞƉƌŽƉŽƐĞĚƐƚƵĚǇ ?ŝƐŶŽƚĐŽƌƌĞĐƚ ?
On the contrary, proposals for pilot studies are not exempt from the need to have a clear and 
ǁĞůů ?ƌĞĂƐŽŶĞĚ ƌĂƚŝŽŶĂůĞ ĨŽƌ ƚŚĞ ŶƵŵďĞƌ ŽĨ ƉĂƌƚŝĐŝƉĂŶƚƐƚŽ ďĞ ŝŶĐůƵĚĞĚ ? ůŝŐŶŵĞŶƚ ŽĨ ƚŚĞ
rationale with the scientific aims of the research is critical. Writing a clear and compelling 
justification for the proposed sample size requires an intellectual analysis of the expected 
benefits, risks, and costs of the study and the knowledge of which statistical methods are 
oƉƚŝŵĂůĨŽƌƚŚĞƐƚƵĚǇ ? “sĂůƵĞŽĨŝŶĨŽƌŵĂƚŝŽŶ ?ƚĞĐŚŶŝƋƵĞƐĂƌĞďĞĐŽŵŝŶŐŵŽƌĞƌĞĐŽŐŶŝǌĞĚĂƐ
alternatives to traditional sample size estimation methods that often rely on imprecise 
parameter inputs (20).  
 
2.4.6. Intervention 
 
The participant activities of the trial should be described in detail. A process flowchart can be 
useful for illustration (Figure 3). 
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Figure 3 Process flowchart illustrating participant activities during the PATHWAY-27 pilot studies 
During the PATHWAY-27 pilot studies volunteers who expressed an interest in taking part in 
the trial were contacted by the RC, provided with the Participant Information Sheet and asked 
to complete a screening questionnaire that gathered information about health and lifestyle 
factors. Subsequently, providing the volunteer did not meet any exclusion criteria, they were 
invited to a screening appointment. At the screening appointment, the study was explained 
to the volunteer in detail, they were given the opportunity to ask questions and it was made 
clear that they had the right to withdraw at any time up until the publication of results. The 
volunteer gave written consent and had their height, weight, waist circumference and blood 
pressure measured, and a sample of blood collected to measure fasting triglycerides, HDL 
cholesterol and glucose. If the results of the screening examination indicated that the 
volunteer met the inclusion criteria they were invited to take part in the trial. A minimum of 
7 days was given prior to baseline to allow potential participants to decide whether they 
wished to take part in the trial.  
 
At the baseline visit to the RC the volunteer was randomised, had physical measurements and 
blood sample collection repeated, and were provided with the study foods. They were 
provided with written study instructions and asked to complete a food frequency 
questionnaire and gastrointestinal symptoms questionnaire. These activities were repeated 
at the endpoint visit with an additional questionnaire that measured acceptance of the BEF. 
During the 28-day intervention period participants were asked to eat one portion of BEF each 
day and to keep a record of the BEF they consumed particularly noting days where BEF were 
not consumed or only part consumed. On Day 1 after eating the BEF for the first-time 
participants were asked to complete the degree of satisfaction questionnaire that measured 
acceptance of the BEF. 
 
2.4.7. Outcomes 
 
Primary and secondary outcomes should be well defined. For health claim applications, EFSA 
will consider whether the outcome describes a beneficial physiological effect, whether the 
outcome variables are direct measures of the claimed effect and if the assessment methods 
are appropriate (16). For a main RCT these will include biochemical markers, anthropometric 
measurements and the data collected from questionnaires. A pilot study will have some of 
the same outcomes, most likely fewer than the main RCT, however the reason for measuring 
these outcomes in a pilot will differ. A pilot study will focus on feasibility or testing analytical 
methods to allow for any necessary improvements to be implemented in the main RCT. In the 
case of PATHWAY-27 the target population was at risk for MetS, which is defined by the 
combination of distinct risk factors. Here, a pilot study gives the opportunity to detect the 
most modifiable risk factor that will serve as primary outcome in the RCT. Any less modifiable 
outcome variable may be considered as a secondary outcome. Additionally, most promising 
outcomes related to a specific intervention may be identified by applying novel analytical 
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(omics) techniques resulting in a single or a set of new markers predictive for a disease or 
function to be implemented in the future RCT. A pilot study could also have a different scope, 
i.e. to select the most promising treatments, as in PATHWAY-27. Any compliance and safety 
markers may be considered as secondary outcomes. In the case of the PATHWAY-27 pilot 
study food derived markers (for example, change in serum DHA after DHA enriched BEF 
consumption) have been determined and included in the compliance analysis. 
 
2.4.8. Analytical and statistical methods 
 
The specific analytical methods required will depend on the parameters being assessed. 
Measurement of biochemical markers will require laboratory analyses. Anthropometric data 
will be collected by trained research personnel directly from the participant. The equipment 
used should be of an appropriate standard to provide accurate and precise measurements 
with a degree of sensitivity that corresponds to the requirements of the study. Validated 
methods should be used, where possible. 
 
2.4.8.1. Analytical methods 
 
 The analytical methods used in the PATHWAY-27 pilot studies are outlined below: 
 
- Blood pressure was measured in participants after being at rest for five minutes in a 
seated position followed by two additional measurements separated by two minutes 
each. A calibrated sphygmomanometer (e.g. Boso-Carat professional) was used and 
the appropriate sized cuff applied after measurement of arm circumference.  
- Height was determined using a calibrated stadiometer.  
- Body weight was measured using a calibrated balance with the participant barefoot 
and dressed in underwear.  
- Waist circumference was measured in standing position between the iliac crest and the 
lowest rib using a measuring tape according to the WHO guideline. 
- Blood sample analyses were performed by standardised automated methods. 
- Food frequency data was captured using the EPIC validated questionnaire. 
- Nuclear magnetic resonance (NMR) spectroscopy was used to measure the 
metabolome of serum. 
 
2.4.8.2. Statistical methods 
 
There are many statistical methods to choose from, with the proper one for a given situation 
depending both on the type of data to be analysed as well as on the question one wants to 
find an answer for. Thus, the t-test can be used for estimating a mean, the difference of two 
means, or to compare two means  W either between groups, or within group (repeated 
measures) or even correlations; ʖ2-tests can be used for estimating proportions, the difference 
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of two proportions, or compare two proportions; the f-test to compare several means, or 
ƉŽƉƵůĂƚŝŽŶǀĂƌŝĂŶĐĞƐ ? Žƌ ƚŚĞ ʖ2-test for the assessment of relationships in two-way tables. 
Thus, several methods will be applied in most of studies, as various types of data are collected 
in the trial, and their assessment will require different methods to be applied (Errore. L'origine 
riferimento non è stata trovata.).  
 
Table 3 Examples of statistical methods and comparisons that can be applied to different data types 
Data Methods Comparisons 
Description of continuous 
variables (such as age, TG 
levels, BMI, etc.) 
- summary statistics including 
number [n], mean, standard 
deviation, median, 
minimum, and maximum 
 
Description of categorical 
variables (such as gender, 
questionnaires, etc.) 
- summary statistics giving 
counts and percentages 
 
Group comparisons - 2 normally distributed 
groups, continuous 
variables 
2-sample t-test 
- 2+ normally distributed 
groups, continuous 
variables 
one-way ANOVA (f-test) 
- 2 or more groups with 
categorical data 
ʖ2-test 
- 2 repeated measures within 
a group 
paired-sample t-test 
- 2+ repeated measures 
within a group 
one-way repeated 
measures ANOVA (f-test) 
- relationship between two 
variables 
correlation analysis 
- relationship between two 
variables, with the 
possibility to adjust for 
confounding factors 
mixed linear model 
 
2.4.9. Safety considerations 
 
Protecting the rights, interests and safety of human participants is fundamental to any 
research study and is governed by the principles of the Nuremberg Code, the Declaration of 
Helsinki and the Council for International Organizations of Medical Sciences (CIOMS). The 
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following list summarises the main points of each guideline, however it is recommended that 
the guidelines are accessed and read fully to ensure complete understanding. 
 
a) Informed consent and the right to withdraw 
b) Risks, burdens and benefits 
c) Vulnerable participants 
d) Ethical review by a research ethics committee 
e) Privacy, confidentiality and anonymity 
f) Use of control/placebo 
g) Scientific validity 
h) Compensation for injury 
i) Research registration, publication and dissemination of results 
 
2.4.9.1. Adverse and serious adverse events 
 
An adverse event (AE) is any medical incident affecting a study participant, it does not 
necessarily have a causal relationship with the study food products. A serious adverse event 
(SAE) is defined as an occurrence that: 
 
- results in death, 
- is life-threatening, 
- requires hospitalisation or prolongation of existing hospitalisation, 
- results in persistent or significant disability or incapacity, 
- consists of a congenital anomaly or birth defect, 
- is otherwise considered medically significant by the investigator. 
 
Provision should be made for the reporting of adverse and serious adverse events to the 
project coordinator. Additionally, events that are considered to be related to the study, or are 
unexpected, should be notified to the REC. 
 
During the PATHWAY-27 pilot studies, clear instructions were given to participants to contact 
a doctor if they experienced an AE or SAE and to inform the RC as soon as possible. 
 
2.4.10. Data management 
 
Data management consists of tasks required to capture all study data into electronic form. It 
includes tasks designed to validate the entered data by means of a variety of edit checks, for 
example subjecting the data to range checks, valid value checks, cross-checks, and manual 
review that provide feedback to those entering/providing the data. A clinical database that 
accurately reflects the data collected and can be used for purposes of analysing study data for 
regulatory submissions and professional publication should be developed.  
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The data capturing process and the electronic system that captures clinical data for purposes 
of analysis and reporting should adhere to Good Clinical Practice (GCP) guidelines for data 
management systems. The standard requirements for high quality GCP-compliant data 
management in multinational clinical trials have been developed by the Working Group on 
Data Centres of the European Clinical Research Infrastructures Network (ECRIN) (21). It 
provides a list of requirements that can be used as a checklist.  
 
During the PATHWAY-27 pilot trials data were initially captured on paper clinical report forms 
(CRF) then transferred to an electronic data capture system (EDC) hosted by AdWare Research 
Ltd. 
 
2.4.11. Quality assurance and quality control 
 
Quality assurance relates to the actions that are established to ensure the trial is conducted 
in compliance with the ICH GCP guidelines and any other relevant regulatory directives. 
 
Quality control refers to the operational practices, within the quality assurance system, that 
are employed to safeguard the activities of the research study satisfying the regulatory 
requirements. 
 
Written Standard Operating Procedures (SOPs) should be developed to ensure the study is 
conducted and that data is generated, documented and reported appropriately. The ICH GCP 
guidelines state that quality control should be applied at each stage of data handling to ensure 
that all data are reliable and have been processed correctly. 
 
It is the responsibility of the sponsor to secure access to all trial-related sites, data, documents 
and reports for monitoring and auditing, and inspection by external regulatory agencies. 
 
2.4.12. Project management and collaborations 
 
The project management structure should be explained along with links to related projects. 
dŚŝƐŝŶĨŽƌŵĂƚŝŽŶǁŝůůďĞǁƌŝƚƚĞŶŝŶƚŽƚŚĞƉƌŽũĞĐƚƐ ?ĞƐĐƌŝƉƚŝŽŶŽĨtŽƌŬƚŽĚĞƐĐƌŝďĞƚŚĞƉƌŽũĞĐƚ
consortium.  
 
2.4.13. Ethics 
 
Adhering to the ICH GCP guidelines, a research trial should be conducted in compliance with 
a protocol that has received institutional review board (IRB)/independent ethics committee 
(IEC) approval/favourable opinion. Each country within the EU will have their own research 
ethics committees that should be consulted in the early stages of planning a research study 
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involving human participants. Academic institutions usually have their own ethics committees 
that are responsible for reviewing research studies that do not involve patients. The European 
Network of Research Ethics Committees (22) provides links to relevant EU and national 
legislation along with details of national research ethics committees. 
 
Errore. L'origine riferimento non è stata trovata. illustrates the ethical approvals required at 
each recruitment centre prior to commencing the PATHWAY-27 pilot studies. 
 
 
 
Table 4 Ethical approvals required at the PATHWAY-27 RCs. CRNH: Centre de Recherche en Nutrition Humaine, France; MRI: 
Max Rubner Institute, Germany; ULE: University of Leeds, UK. 
CRNH MRI ULE 
- CPP Sud Est VI (ethics 
committee of Clermont-
Ferrand) 
- ANSM (French drugs 
Agency, Vigilance system 
to clinical trials) 
- Ethics Committee of the 
State Chamber of 
Physicians in Baden-
Württemberg (Ethik-
Kommission der 
Landesärtzekammer 
Baden Württemberg) 
- University of Leeds 
Faculty Research Ethics 
Committee 
- NHS R&D required for 
the use of NHS services 
(for example blood 
sample analyses) 
 
2.4.13.1. Approvals and amendments 
 
Substantial amendments such as changes to the study protocol or other recruitment 
documents and procedures will require an ethics amendment before being implemented. 
Ethics applications and amendments can take many weeks to be considered and given a 
favourable opinion. Amendments are usually reviewed more quickly although multiple 
substantial amendments to the study protocol may require submission of a new ethics 
application and therefore be subject to the full ethics review process.  
 
2.4.14. Budget and funding 
 
Within this section full details of the budget requested should be provided, with justifications 
for each item, and sources of financial support for the project. 
 
An example summary of costs to be included in the budget proposal is provided in Errore. 
L'origine riferimento non è stata trovata.. 
 
Table 5 Example of costs to be considered for a dietary intervention trial 
Cost item Description 
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Infrastructure and facilities Buildings, utilities, insurance etc. 
Staff salaries PI, Co-ordinator, Nurse, Technician, Clerical etc. 
Consumables Blood and urine sample collection, sample processing and 
storage, sample despatch to analysing laboratories etc.  
Participant payments Commensurate with the time and effort expended by the 
participant* 
 
*Payments to participants, or compensation for time and effort, is specific to each country 
and will be influenced by the recommendations of the REC.   
 
 
 
 
2.4.15. Finance and insurance 
 
The agreements for financial support and insurance should be provided. For example, the 
PATHWAY-27 project is funded by the EU Seventh Framework Programme. Insurance and/or 
indemnity to meet potential legal liabilities is provided by the Sponsor, which in this case is 
the recruitment centre. 
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3. Implementing a pilot study 
 
It is essential to have a detailed plan for food production and recruitment. BEF will typically 
have a shorter shelf life than a dietary supplement in the form of a pill so the production and 
recruitment plans must be strategically developed and closely monitored to complement each 
other. BEF must be produced, dispatched and available at the RC ready for distribution to the 
participants as necessary. 
 
3.1. Food production plan 
 
The food production plan must be developed in conjunction with the food manufacturer to 
consider availability of equipment and production capacity at the production facility, as well 
as the storage capacity of the RC taking into account the product shelf life, requirements for 
microbiological testing and the transportation time. The food production plan will also be 
influenced by the study design requirements, such as randomization and gender stratification. 
For the PATHWAY-27 pilot studies block randomization was stratified by gender. BEF were 
produced separately for men and women. The randomization by gender complicated the 
production plan and therefore this type of randomisation was not adopted for the larger trial. 
 
3.1.1. Deliveries to RC 
 
BEF shipments must take into consideration weekends and national holidays at the RC. 
Deliveries may be made on a large pallet so there should be a suitable facility at the RC to 
unload this type of shipment from the delivery vehicle. In some cases, where the shipment is 
small, boxes can be unloaded individually, however it may be impractical to do this with a 
large number of boxes, particularly in the case of frozen BEF that must be transferred to frozen 
storage as quickly as possible to maintain the cold chain. 
 
3.1.2. Storage facilities 
 
Ambient BEF are easier to store than BEF that require cold storage. The storage facility should 
be adequately constructed to maintain the quality of the foods during the shelf-life, this may 
be to protect against high temperature, light, moisture and pest infestation. Cold storage will 
be regulated by national legislation, for example in England quick frozen foods, such as the 
pancakes used in the PATHWAY-27 trial, are covered by the Quick Frozen Foodstuffs (England) 
Regulations 2007 (23). This regulation states that the temperature on thermal stabilization 
must be -18°C or colder and that this temperature must be maintained, except for brief 
periods during transport (including local distribution), where it may reach -15°C, or when in 
retail display cabinets where it may reach -12°C. Air temperature must be monitored during 
transport and storage. Where the cold storage facility at the RC is less than 10m3 this may be 
limited to an externally visible thermometer.  
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3.1.3. Unused food 
 
In the event that the recruitment target is not fully achieved and BEF are not used it should 
be decided whether foods can be recycled or destroyed. If possible BEF should be recycled for 
other participants in the trial to reduce unnecessary food wastage and additional 
production/shipping costs being incurred. If storage space is restricted at the RC, having a 
contingency plan to recycle or destroy foods will help to reduce the burden of storing foods 
that will not be used. 
 
3.2. Recruitment plan 
 
The recruitment plan will be developed in conjunction with the recruitment centres and food 
manufacturers considering the capacity for appointments and food production, respectively. 
The rate of recruitment and randomization to the trial must match the rate of food production 
and delivery to the RC to ensure the availability of BEF for each participant. 
 
3.2.1. Recruitment strategies 
 
Accessing a target group with a specific health condition and motivating that group to take 
part in a dietary intervention trial can be challenging. If the health condition manifests through 
poor dietary and lifestyle choices it can be difficult to motivate such individuals to volunteer 
to a trial that involves changing firmly established behaviours. Experience from the PATHWAY-
27 study indicates that volunteers to a dietary intervention trial are often interested in their 
diet and health and therefore typically have a healthy metabolic profile. Consequently, they 
are not eligible to take part in a trial that requires participants with an unhealthy metabolic 
profile, for example elevated fasting blood triglycerides and/or low HDL cholesterol. Members 
of the public with an unhealthy metabolic profile, and who are often unaware of it, are less 
likely to be motivated to volunteer to take part in a dietary intervention trial. 
 
Recruitment strategies are a key component to accessing the target group. Advertising the 
trial using the most effective media will help to improve the success rate of recruitment. The 
pilot study can be used to test different advertising methods and identify the most suitable 
for the target population. Advertising can be broadly focused to a non-specific audience, for 
example on a local radio station, or directly targeted to identify potential participants from a 
clinical patient register, for example at a local ĚŽĐƚŽƌ ?Ɛ surgery.  
 
A radio advert may reach many thousands of listeners and generate a lot of enquiries about 
the study. Translating those enquiries to participants requires an effective management 
system since it will not be feasible to speak directly with each advert respondent. A dedicated 
website or page on the RCs website is a useful first point of contact for enquiries where 
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information about the trial can be conveyed. A link on the webpage can direct volunteers to 
an online survey that can be initially used to filter out individuals based on some of the 
exclusion criteria. For example, if treatment with statins is an exclusion criterion there can be 
a question on the survey that asks whether the respondent currently takes statins. If the 
ĂŶƐǁĞƌ ŝƐ  ?ǇĞƐ ? ƚŚĞƐƵƌǀĞǇĐĂŶprovide an automatic message informing the individual that 
they are not eligible to participate. At the end of the survey, respondents who are eligible to 
continue with selection are asked to provide contact details that are collected by the RC. 
Subsequently potential participants can be contacted and asked to complete a secondary 
online survey that is used to collect more specific data from volunteers, such as date of birth, 
height and weight, physical activity, allergies, current medication and health conditions. This 
data can be used to identify potential participants and invite them to a screening 
appointment, and to exclude those who meet exclusion criteria. 
 
3.2.2. Food distribution to participants 
 
Distributing BEF to participants will be influenced by the BEF storage conditions, shelf-life and 
ƐƚŽƌĂŐĞĐĂƉĂĐŝƚǇĂƚƚŚĞƉĂƌƚŝĐŝƉĂŶƚƐ ?ŚŽŵĞ ? BEF with a long shelf-life, such as the PATHWAY-
27 milkshake powders that are stored ambiently and provided in a small sachet, pose very 
little problem for distribution. In this instance, it may only be necessary for one delivery. BEF 
that have a limited shelf-life may require more frequent deliveries. The bioactive stability of 
PATHWAY-27 biscuits dictated the shelf-life of the product. Short study duration, such as the 
4-week pilot trial, only required one delivery to each participant. By contrast, a trial with 
duration longer than the shelf-life of the BEF would require more deliveries. BEF requiring cold 
storage are likely to pose the greatest storage problems. Firstly, it is important to note that 
the requirement for a freezer Ăƚ ƚŚĞ ƉĂƌƚŝĐŝƉĂŶƚƐ ? ŚŽŵĞ becomes an additional exclusion 
criterion. Providing that the participant has a freezer, the capacity needs to be considered. 
Short trial duration may be less problematic whereas a longer trial may necessitate multiple 
deliveries. In some instances, PATHWAY-27 pancakes had to be delivered to the home of the 
participants by research staff, since the participant could either not return home immediately 
after visiting the RC or they did not have suitable transport. 
 
3.2.3. Participant retention and compliance 
 
One of the most important aspects of conducting the trial is the retention and compliance of 
participants. Motivation for taking part in a trial varies between participants. Predominantly, 
in the PATHWAY-27 project, volunteers were motivated by potential for weight-loss, even 
though this was not a primary outcome of the study (this was clearly explained upon 
recruitment). If the participant does not feel that their personal objective for taking part in 
the trial is being met, they may lose motivation and withdraw.  
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The ease with which a participant integrates the BEF into their usual diet will influence their 
motivation. If the BEF are not well accepted then compliance to the study protocol will be 
impaired and may even lead to participants choosing to withdraw from the trial. Examples of 
how the foods could be consumed was provided (e.g. pancakes can be eaten on their own, or 
with sweet or savoury fillings). The time and effort that is required from a participant will also 
influence compliance and retention. A short trial that requires a participant to consume one 
BEF per day with relatively few questionnaires and visits to the RC will be more accepted than 
a longer trial with multiple foods and/or multiple questionnaires and visits to the RC. 
 
Regular communication with each participant is essential to develop and maintain a good 
relationship. Participants who feel valued and well-informed will be more motivated to 
consume the BEF, complete the questionnaires and come to the RC when required. There are 
exceptions when participants are simply not well motivated, however in these cases it is 
unlikely that the research team will be able to improve compliance or prevent withdrawal 
from the trial. 
 
3.2.4. Sample collection 
 
For a human study investigating the effect of BEF on physiologically-relevant endpoints it is 
likely that biological samples will be required for analyses. The type of sample will depend on 
the selected endpoints but as a minimum requirement blood and possibly urine will be 
collected. It is common to collect a fasted sample from participants, particularly when 
measuring analytes that are influenced by consumption of food, such as glucose and 
triglycerides that will increase after a meal. To measure baseline values a fasting period of 10-
12 hours may be necessary. 
 
In some cases, it might be sufficient to use a point-of-care device such as the Cardiochek 
Professional Analyser test system that can measure the concentration of single or multiple 
analytes, using analyte-specific test strips, in a small volume of capillary blood (15-40 µL) 
collected from a fingertip. This can be useful for screening volunteers as the results are 
available within a few minutes. In most cases it is more appropriate to collect larger volumes 
of blood to perform a wider range of analyses. In this case a trained phlebotomist will be 
required to perform venepuncture, typically on the antecubital fossa region.  
 
It is essential to determine the biological markers prior to the start of the trial to ensure the 
most suitable blood collection tubes are used. The number and type of analytes to be 
measured will influence the tube volume and additive type. The volume of blood drawn should 
not be excessive to minimise discomfort to the participant. Ethically it will be important to 
justify the volume required. The correct tube type will depend on the analyte being measured 
and the analytical method. For example, to measure lipids it is necessary to collect blood into 
a tube containing a coagulant that causes the blood to clot. The tube is typically left for 30 
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minutes at room temperature following blood collection to allow the clot to form. The tube 
can then be centrifuged to separate the sample and extract serum. Multiple tube collections 
must adhere to recommendations for the order of draw to prevent potential cross-
contamination of additives that may affect the accuracy of sample analyses. Current practice 
for the order of draw is: 
 
1) Blood cultures 
2) Citrate 
3) Serum 
4) Heparin 
5) EDTA 
6) Fluoride 
 
Some analytical methods will require the sample to be refrigerated immediately after 
collection to prevent sample/analyte degradation, in other cases it may not be necessary. In 
all cases it is essential to know the correct storage conditions for the sample, use suitable 
storage containers that are appropriate for the storage conditions and to label the samples 
adequately to guarantee traceability. 
 
3.2.5. Sample analysis 
 
The protocols for sample analyses should be determined prior to the start of the trial. Changes 
to the analytical protocols, including changing equipment or laboratories, during the trial 
should be avoided as this could introduce a source of error into the results. Failure to manage 
the samples correctly may affect the accuracy of the analyses. If there are special conditions 
that are required for the processing and storage of samples they must be communicated to 
the research team involved with collection and processing of samples. For samples that are to 
be stored prior to being shipped to the analytical laboratory, it is essential that the storage 
conditions are maintained during transport, where necessary. Repeated freeze-thaw cycles 
may reduce the integrity of the sample and affect the results. For example, serum obtained 
for the analysis of lipids, glucose, thyroid, kidney and liver function in the PATHWAY-27 
project, is stored at -80°C and must maintain its frozen state until it is required for analysis. By 
contrast, whole blood used to analyse single nucleotide polymorphisms (SNPs) is stored at -
20°C at the RC but can be shipped at ambient temperature. 
 
Ideally all samples will be analysed by one laboratory to limit sources of random error. For 
multi monocentric studies, such as the PATHWAY-27 pilot studies, it is acceptable for sample 
analyses to be conducted at different laboratories however the analytical method, including 
the type of sample used  W for example serum or plasma, should be the same. For a multi-
centre trial (PATHWAY-27 larger trial), the analyses should, where practicable, be done by a 
centralised laboratory. In some cases, it is not feasible to use one analytical laboratory due to 
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the type of analysis that is to be performed. For example, a full blood count requires relatively 
fast analysis of whole blood to prevent artefacts from the EDTA anticoagulant that affect the 
results. 
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4. Reporting a pilot study 
 
4.1. Pilot study outcomes 
 
As discussed previously, the aim of a pilot study is to test the study protocol as well as 
addressing whether consumption of a particular BEF causes a beneficial physiological effect. 
The pilot study outcomes will be used to inform decisions for a subsequent RCT. Using the 
PATHWAY-27 pilot study as an example, the following outcomes were achieved: 
 
- Primary outcomes measured at baseline and endpoint 
 Fasting blood triglycerides 
 HDL cholesterol 
- Secondary outcomes measured at baseline and endpoint 
 Fasting blood glucose 
 Body height, weight and BMI 
 Waist circumference 
 Blood pressure 
- Acceptance of BEF 
- Participant compliance with the study protocol 
- Participant recruitment strategies 
- Testing of data collection methods 
- Logistics of food delivery and storage 
- BEF selection for main RCT 
 
Collating the pilot study outcomes and using them to learn what works well and what doeƐŶ ?ƚ ?
then implementing any necessary changes will help to ensure the subsequent RCT has a good 
quality, robust design that will provide substantial evidence to support the claim of a 
beneficial health effect. 
 
4.2. CONSORT 2010 Statement: extension to randomised pilot and feasibility trials 
 
One of the main outputs of a research study is the dissemination of results. The Consolidated 
Standards of Reporting Trials (CONSORT) 2010 guidelines (24) were developed to improve 
reporting of RCTs. Transparency is the core objective. 
 
The CONSORT statement provides a minimum set of recommendations for reporting RCTs 
with a series of extension statements to include variations of the standard trial methodology. 
For example, the CONSORT statement for pilot and feasibility trials (25) provides guidance for 
reporting randomised trials in which a prospective RCT, or part of it, is conducted on a smaller 
scale. 
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The CONSORT statement: extension to randomised pilot and feasibility trials comprises a 
checklist of items that should be included in the report. The main points of the checklist are 
summarised below: 
 
a) Title and abstract 
b) Introduction 
- Background and objectives 
c) Methods 
- Trial design 
- Participants 
- Intervention 
- Outcomes 
- Sample size 
- Randomisation 
- Sequence generation 
- Allocation concealment mechanism 
- Implementation 
- Blinding 
- Analytical methods 
d) Results 
- Participant flow 
- Recruitment 
- Baseline data 
- Numbers analysed 
- Outcomes and estimations 
- Ancillary analyses 
- Harms 
e) Discussion 
- Limitations 
- Generalisability 
- Interpretation 
f) Other information 
- Registration 
- Protocol 
- Funding 
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5. Conclusion 
 
Valuable experiences gathered from the PATHWAY-27 pilot studies have been collated and 
presented here with the aim of providing a useful guidance document for health researchers. 
A well-designed pilot trial can improve the quality and robustness of a larger RCT. Dietary 
intervention trials are complex and often involve asking participants to consume foods that 
they would not usually choose to eat and to change behaviours that have developed over 
many years. BEF add an additional level of complexity since the food product is novel and 
experimental and therefore unfamiliar to most consumers. For SMEs to invest time and 
money in R&D there has to be an incentive, such as gaining market competitiveness. This may 
be achieved through successful health claim applications that allow the SME to market and 
promote their food as beneficial to health. Achieving a successful health claim application for 
a functional food requires formulation of a BEF that is well characterised and can be shown to 
have a beneficial physiologically-relevant effect on health. Strategic planning and close 
collaboration between all relevant partners (production companies, researchers, co-
ordinators) is central to designing and implementing a pilot study and subsequent larger RCT 
that will generate exploitable outcomes. 
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